Catal­ent’s Q3 rev­enue fell 19% in de­layed re­veal of fi­nan­cial re­sults

Catal­ent said rev­enue in its bi­o­log­ics man­u­fac­tur­ing busi­ness tum­bled 32% in the third quar­ter, dri­ven by a drop-off in sales of Covid-19 vac­cines.

The em­bat­tled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER